CEO Greg Duncan Talks Virios Therapeutics (VIRI)

Schwab Network

English - April 20, 2021 18:00 - 6 minutes - 45.3 MB - ★★★★★ - 23 ratings
News Commentary News Business News business news news commentary news Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Cyclical & Growth Positioning: Energy, Financials, & Tech

Next Episode: Netflix Earnings Expectations

The CEO and Chairman of the Board of Directors of Virios Therapeutics (VIRI), Greg Duncan, says that the clinical-stage biotechnology company is focused on novel, dual mechanism antiviral therapies to treat chronic debilitating diseases like fibromyalgia. The stock began trading on the Nasdaq in December 2020.